Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia

定义 METTL3 在慢性淋巴细胞白血病发病机制中的致癌作用

基本信息

  • 批准号:
    10717803
  • 负责人:
  • 金额:
    $ 55.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-07-01 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary Aggressive chronic lymphocytic leukemia (CLL) remains incurable despite with improved chemotherapy regimens and targeted therapies. Better understanding of the biology underlying aggressive CLL is expected to design novel therapies. We recently discovered that high spliceosome complex protein expression results in aberrant RNA splicing, is associated with aggressive disease and serves as an independent predictive marker for poor prognosis in CLL, highlighting RNA splicing dysregulation underlies aggressive CLL. Through an integrated transcriptome and proteome analysis on normal and primary CLL B cells, we discovered that METTL3, an RNA methyltransferase that deposits N6-methyladenosine (m6A) modification on mRNA, is strongly implicated as a key regulator for RNA splicing in CLL. METTL3 is a highly expressed protein in CLL, associated with poor clinical outcome, and significantly correlated with splicing factor protein expression. Moreover, efficacious small molecule inhibitors of METTL3 have been developed and have shown promising results in hematological malignancy. Treatment with METTL3 inhibitor results in growth defect in CLL cell lines and decreases RNA splicing factor protein expression. Moreover, we have obtained evidence that METTL3 overexpression is oncogenic by rending IL-3 independency in Ba/F3 cell line model. Based on these preliminary data, we hypothesize that METTL3 potentially acts as an oncogene and drives the onset and progression of CLL through the regulation of RNA splicing network, making it a potential target for treating aggressive CLL. To address this hypothesis, we propose to investigate METTL3 is required for both development and maintenance of CLL using murine models (Aim 1). We will dissect the molecular mechanism underlying the targets of RNA splicing network in CLL and understand how they are regulated by METTL3 (Aim 2). Moreover, we will determine whether METTL3 is a viable therapeutic target in treating aggressive CLL and if targeting both METTL3 and RNA splicing regulatory network has a synergistic effect in CLL (Aim 3). Collectively, the results of the experiments proposed in this application will establish METTL3 as an CLL oncogene, elucidate the m6A-modification on target transcripts that modulated by METTL3 to promote and maintain CLL, and evaluate a new therapeutic approach for aggressive CLL.
项目摘要 侵袭性慢性淋巴细胞白血病(CLL)尽管化疗得到改善,但仍然无法治愈 方案和靶向治疗。更好地理解侵袭性CLL的生物学基础, 设计新的疗法。 我们最近发现,高剪接体复合蛋白表达导致RNA剪接异常, 与侵袭性疾病相关,并作为CLL预后不良的独立预测标志物, 突出RNA剪接失调是侵袭性CLL的基础。通过整合的转录组, 通过对正常和原代CLL B细胞的蛋白质组分析,我们发现胃L3,一种RNA甲基转移酶, 在mRNA上沉积N6-甲基腺苷(m6 A)修饰,强烈暗示是RNA的关键调节因子 CLL中的剪接。CLL中L3是一种高表达的蛋白质,与临床结局差相关, 与剪接因子蛋白表达显著相关。此外,有效的小分子抑制剂, 已经开发了胃L3,并在血液恶性肿瘤中显示出有希望的结果。治疗 胃L3抑制剂导致CLL细胞系的生长缺陷并降低RNA剪接因子蛋白表达。 此外,我们已经获得证据表明,胃L3过表达是通过使IL-3非依赖性致癌的, 在Ba/F3细胞系模型中。基于这些初步数据,我们假设胃L3可能作为一种 癌基因,并通过调节RNA剪接网络驱动CLL的发作和进展, 它是治疗侵袭性CLL的潜在靶点。为了解决这一假设,我们建议研究胃L3 是使用鼠模型发展和维持CLL所必需的(Aim 1)。我们将解剖 CLL中RNA剪接网络靶点的分子机制,并了解它们是如何 受AAPL 3(目标2)监管。此外,我们将确定胃L3是否是一个可行的治疗靶点, 治疗侵袭性CLL,如果靶向胃L3和RNA剪接调控网络, 对慢性淋巴细胞白血病(CLL)的影响(目标3)。 总的来说,本申请中提出的实验的结果将确立胃L3作为CLL 癌基因,阐明m6 A修饰的目标转录本,调节胃L3,以促进和 维持CLL,并评估侵袭性CLL的新治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lili Wang其他文献

Lili Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lili Wang', 18)}}的其他基金

Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia
SF3B1突变和ATM缺失在慢性淋巴细胞白血病发病机制中的协同作用
  • 批准号:
    10376233
  • 财政年份:
    2020
  • 资助金额:
    $ 55.62万
  • 项目类别:
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia
SF3B1突变和ATM缺失在慢性淋巴细胞白血病发病机制中的协同作用
  • 批准号:
    10116331
  • 财政年份:
    2020
  • 资助金额:
    $ 55.62万
  • 项目类别:
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia
SF3B1突变和ATM缺失在慢性淋巴细胞白血病发病机制中的协同作用
  • 批准号:
    9974178
  • 财政年份:
    2020
  • 资助金额:
    $ 55.62万
  • 项目类别:
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia
SF3B1突变和ATM缺失在慢性淋巴细胞白血病发病机制中的协同作用
  • 批准号:
    10597240
  • 财政年份:
    2020
  • 资助金额:
    $ 55.62万
  • 项目类别:
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
(PQ8) 用于研究慢性淋巴细胞白血病疾病进展的遗传忠实小鼠模型
  • 批准号:
    10161748
  • 财政年份:
    2017
  • 资助金额:
    $ 55.62万
  • 项目类别:
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
(PQ8) 用于研究慢性淋巴细胞白血病疾病进展的遗传忠实小鼠模型
  • 批准号:
    9924248
  • 财政年份:
    2017
  • 资助金额:
    $ 55.62万
  • 项目类别:
CORE--VECTOR PRODUCTION
核心——矢量制作
  • 批准号:
    6919791
  • 财政年份:
    2004
  • 资助金额:
    $ 55.62万
  • 项目类别:
Core--Vector
核心--向量
  • 批准号:
    6775151
  • 财政年份:
    2003
  • 资助金额:
    $ 55.62万
  • 项目类别:
CORE--VECTOR PRODUCTION
核心——矢量制作
  • 批准号:
    7110301
  • 财政年份:
  • 资助金额:
    $ 55.62万
  • 项目类别:
Barriers to achieving efficient gene therapy
实现有效基因治疗的障碍
  • 批准号:
    8652991
  • 财政年份:
  • 资助金额:
    $ 55.62万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 55.62万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 55.62万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 55.62万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 55.62万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 55.62万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 55.62万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 55.62万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 55.62万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 55.62万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 55.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了